Matthew Link Sells 5,042 Shares of Sight Sciences, Inc. (NASDAQ:SGHT) Stock

Sight Sciences, Inc. (NASDAQ:SGHT - Get Free Report) insider Matthew Link sold 5,042 shares of the stock in a transaction on Wednesday, April 2nd. The stock was sold at an average price of $2.31, for a total value of $11,647.02. Following the completion of the transaction, the insider now owns 830,551 shares of the company's stock, valued at $1,918,572.81. The trade was a 0.60 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Sight Sciences Price Performance

Shares of Sight Sciences stock traded down $0.10 during trading on Tuesday, hitting $2.11. 91,285 shares of the company were exchanged, compared to its average volume of 209,147. Sight Sciences, Inc. has a fifty-two week low of $2.04 and a fifty-two week high of $8.45. The company has a quick ratio of 9.74, a current ratio of 10.18 and a debt-to-equity ratio of 0.36. The firm has a 50 day moving average price of $2.66 and a 200 day moving average price of $3.78. The stock has a market capitalization of $108.31 million, a price-to-earnings ratio of -2.06 and a beta of 2.46.

Sight Sciences (NASDAQ:SGHT - Get Free Report) last posted its quarterly earnings data on Wednesday, March 5th. The company reported ($0.23) EPS for the quarter, missing analysts' consensus estimates of ($0.22) by ($0.01). The company had revenue of $19.07 million for the quarter, compared to analyst estimates of $18.98 million. Sight Sciences had a negative net margin of 63.30% and a negative return on equity of 47.28%. During the same period in the previous year, the business earned ($0.22) EPS. On average, equities analysts expect that Sight Sciences, Inc. will post -0.99 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on SGHT shares. Piper Sandler cut their price target on shares of Sight Sciences from $5.50 to $3.50 and set a "neutral" rating for the company in a report on Thursday, March 6th. Needham & Company LLC reaffirmed a "hold" rating on shares of Sight Sciences in a report on Thursday, March 6th. Lake Street Capital reduced their price target on shares of Sight Sciences from $3.00 to $2.50 and set a "hold" rating for the company in a research report on Thursday, March 6th. Stifel Nicolaus lowered their price target on Sight Sciences from $5.00 to $4.00 and set a "buy" rating on the stock in a report on Thursday, March 6th. Finally, UBS Group reduced their price objective on Sight Sciences from $5.50 to $5.00 and set a "buy" rating for the company in a report on Monday, January 27th. Five investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat.com, Sight Sciences presently has an average rating of "Hold" and a consensus target price of $3.83.

Institutional Trading of Sight Sciences

Hedge funds have recently bought and sold shares of the company. ProShare Advisors LLC acquired a new position in Sight Sciences in the 4th quarter valued at $36,000. Dynamic Technology Lab Private Ltd acquired a new position in Sight Sciences in the fourth quarter valued at $40,000. Arkadios Wealth Advisors acquired a new position in Sight Sciences in the fourth quarter valued at $47,000. WealthTrust Asset Management LLC purchased a new position in Sight Sciences during the fourth quarter worth about $48,000. Finally, Mitsubishi UFJ Asset Management Co. Ltd. acquired a new stake in Sight Sciences in the 4th quarter worth about $50,000. Institutional investors and hedge funds own 55.51% of the company's stock.

Sight Sciences Company Profile

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.